What is Esperion Therapeutics Inc (ESPR) stock price today?

Esperion Therapeutics Inc (ESPR) currently trades at $2.00 per share. The stock has a market capitalization of $491.64M and a P/E ratio of —x.

Is ESPR stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Esperion Therapeutics Inc has a Smart Value Score of 44/100 (Grade D), resulting in a "Sell" investment rating. The Piotroski F-Score is —/9 and Altman Z-Score is —.

What is Esperion Therapeutics Inc's revenue and earnings?

Esperion Therapeutics Inc has trailing twelve-month (TTM) revenue of $403.13M with profit margins of -5.63%. Earnings per share (EPS) is $-0.11.

ESPR

Esperion Therapeutics Inc

NASDAQ: ESPR · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC

$2.00

+4.71% today

Updated 2026-04-30

Market cap

$491.64M

P/E ratio

—

P/S ratio

1.22x

EPS (TTM)

$-0.11

Dividend yield

—

52W range

$1 – $4

Volume

6.1M

Market cap

$491.64M

P/E ratio

—

P/S ratio

1.22x

EPS (TTM)

$-0.11

Dividend yield

—

52W range

$1 – $4

Volume

6.1M

WallStSmart proprietary scores

out of 100

Grade: D

Sell

Investment rating

8.0

Growth

5.0

Quality

C+

5.5

Profitability

C+

5.0

Valuation

C+

—/9

Piotroski F-Score

—

Altman Z-Score

—

Industry rank

—

View all highly rated stocks (75+) →200 stocks currently score above 75

Price targets

Analyst target

$6.74

+237.00%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

3 Strong Buy2 Buy1 Hold0 Sell1 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ Free cash flow $45.05M — positive

+ Revenue growth 143.70% QoQ

Risks

- Thin margins at -5.63%

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$75.47M	$116.33M	$332.31M	$403.13M	$403.13M
Net income	$-233.66M	$-209.25M	$-51.74M	$-22.68M	$61.83M
EPS	—	—	—	—	$-0.11
Free cash flow	$-174.83M	$-135.49M	$-23.97M	$-13.28M	$45.05M
Profit margin	-309.58%	-179.87%	-15.57%	-5.63%	-5.63%

Recent insider activity

Date	Insider	Type	Shares	Price
2026-03-17	LOOKER, BENJAMIN	Sale	5,708	$2.70
2026-03-17	KOENIG, SHELDON L.	Sale	25,578	$2.72
2026-03-17	HALLADAY, BENJAMIN	Sale	6,424	$2.71

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
ESPR	$491.64M	44	8.0	5.5	5.0	5.0	—	Hold
LLY	$789.69B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.64B	59	4.7	9.0	3.3	6.0	-41.97%	Buy
ABBV	$351.47B	63	4.0	8.0	4.7	5.0	-24.92%	Buy
UNH	$322.34B	54	5.3	5.5	7.3	4.8	+42.06%	Buy
AZN	$294.17B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Esperion Therapeutics Inc trades at $2.00. Our Smart Value Score of 44/100 indicates the stock is fair. TTM revenue stands at $403.13M. with profit margins at -5.63%.

Frequently asked questions

What is Esperion Therapeutics Inc's stock price?

Esperion Therapeutics Inc (ESPR) trades at $2.00.

Is Esperion Therapeutics Inc overvalued?

Smart Value Score 44/100 (Grade D, Sell).

What is the price target of Esperion Therapeutics Inc (ESPR)?

The analyst target price is $6.74, representing +237.0% upside from the current price of $2.00.

What is Esperion Therapeutics Inc's revenue?

TTM revenue is $403.13M.

Company info

SectorHEALTHCARE

IndustryDRUG MANUFACTURERS - SPECIALTY & GENERIC

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio1.22x

ROE-260.80%

Beta1.17

50D MA$2.69

200D MA$2.77

Shares out0.26B

Float0.25B

Short ratio—

Avg volume6.1M

Performance

1 week-0.52%

1 month-30.29%

3 months-44.15%

YTD-48.38%

1 year—

3 years—

5 years—

Compare

ESPR vs LLY →ESPR vs JNJ →ESPR vs ABBV →Stock screener →